Specific organization for in‐hospital belatacept infusion to avoid nosocomial transmission during the SARS‐CoV‐2 pandemic

Nassim Kamar (1, 2) , Laure Esposito (2) , Anne Hebral (2) , Joelle Guitard (2) , Arnaud del Bello (1, 2)

1 CPTP - Centre de Physiopathologie Toulouse Purpan
2 Service de Néphrologie - Immunologie Clinique [Toulouse]

The first cases of Severe Acute Respiratory Syndrome coronavirus 2 (SARS‐CoV‐2) occurred in France in early February and in our region (Southwest France) in early March 2020.

Mots clés: clinical research/practice; complication: infectious; immunosuppressant-fusion proteins and monoclonal antibodies: belatacept; immunosuppression/immune modulation; infectious disease.

Domaines: Maladies infectieuses

Nassim Kamar, Laure Esposito, Anne Hebral, Joelle Guitard, Arnaud del Bello. Specific organization for in‐hospital belatacept infusion to avoid nosocomial transmission during the SARS‐CoV‐2 pandemic. American Journal of Transplantation, 2020, 20 (10), pp.2962-2963. ⟨10.1111/ajt.16074⟩. ⟨hal-03160620⟩